Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jul 23;332(4):337.
doi: 10.1001/jama.2024.10480.

Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer

Hengjia Tu  1 , Yuzhuo Zhang  1 , Zhixuan You  1
Affiliations
Comment

Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer

Hengjia Tu et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Leon-Ferre reported receipt of consulting honoraria to his institution for research activities from AstraZeneca, Gilead Sciences, and Lyell Immunopharma. Dr Salgado reported advisory board membership for Roche, Bristol Myers Squibb, Exact Sciences, and AstraZeneca; receipt of research funding from Merck; and consulting for Owkin and Daiichi Sankyo. No other disclosures were reported.

Comment in

Comment on

  • Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Leon-Ferre RA, et al. JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056. JAMA. 2024. PMID: 38563834 Free PMC article.

References

    1. Leon-Ferre RA, Jonas SF, Salgado R, et al. ; International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331(13):1135–1144. doi: 10.1001/jama.2024.3056 - DOI - PMC - PubMed
    1. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–1452. doi: 10.1093/jnci/djp335 - DOI - PMC - PubMed
    1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi: 10.1200/JCO.2005.04.7985 - DOI - PubMed
    1. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi: 10.1016/S1470-2045(17)30904-X - DOI - PubMed
    1. Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569. doi: 10.1200/JCO.18.01010 - DOI - PMC - PubMed